Idiopathic pneumonia syndrome

From WikiMD's WELLNESSPEDIA


Idiopathic pneumonia syndrome
Synonyms IPS
Pronounce N/A
Specialty N/A
Symptoms Cough, dyspnea, hypoxemia, fever
Complications Respiratory failure, acute respiratory distress syndrome
Onset Variable
Duration Variable
Types N/A
Causes Unknown
Risks Hematopoietic stem cell transplantation, chemotherapy, radiation therapy
Diagnosis Clinical diagnosis, exclusion of other causes
Differential diagnosis Infectious pneumonia, pulmonary edema, graft-versus-host disease
Prevention N/A
Treatment Supportive care, corticosteroids
Medication N/A
Prognosis Variable, often poor
Frequency Rare
Deaths N/A


Idiopathic Pneumonia Syndrome (IPS) is a non-infectious lung disorder that is primarily observed in patients who have undergone hematopoietic stem cell transplantation (HSCT). The syndrome is characterized by widespread injury to the lung tissue without a detectable infection.

Etiology[edit]

The exact cause of IPS is unknown, hence the term "idiopathic". However, it is believed to be a result of damage to the lung tissue caused by the preparative regimen for HSCT. This regimen often includes high-dose chemotherapy and radiation therapy, which can cause significant damage to the lung tissue.

Clinical Presentation[edit]

Patients with IPS typically present with symptoms of respiratory distress, such as shortness of breath, cough, and fever. These symptoms usually occur within the first 120 days following HSCT. On imaging studies, such as a chest radiograph or CT scan, diffuse abnormalities can be seen throughout the lungs.

Diagnosis[edit]

The diagnosis of IPS is made based on the clinical presentation and imaging findings, in the absence of a detectable infection. Other potential causes of lung injury, such as pneumonia, must be ruled out. A lung biopsy may be performed to confirm the diagnosis.

Treatment[edit]

The primary treatment for IPS is supportive care, including oxygen therapy and mechanical ventilation if necessary. In some cases, high-dose corticosteroids may be used to reduce inflammation in the lungs. However, the overall prognosis for patients with IPS is poor, with a high mortality rate.

See Also[edit]